Breaking News Instant updates and real-time market news.

TEVA

Teva

$10.57

-0.145 (-1.35%)

, MNK

Mallinckrodt

$3.74

0.135 (3.75%)

13:00
11/26/19
11/26
13:00
11/26/19
13:00

Federal criminal probe launched into opioid makers and distributors, WSJ says

Federal prosecutors have opened a criminal investigation into whether drug companies alleged to have contributed to the opioid epidemic intentionally allowed opioid painkillers to flood communities, according to The Wall Street Journal's Corinne Ramey, citing people familiar with the matter. At least six companies have previously said in regulatory filings that they received grand-jury subpoenas from the U.S. attorney's office in the Eastern District of New York - Teva Pharmaceutical (TEVA), Mallinckrodt (MNK), Johnson & Johnson (JNJ), Amneal Pharmaceuticals (AMRX), AmerisourceBergen (ABC) and McKesson (MCK) - and people familiar with the matter said the subpoenas were in connection with the Brooklyn federal probe, the report noted. Reference Link

TEVA

Teva

$10.57

-0.145 (-1.35%)

MNK

Mallinckrodt

$3.74

0.135 (3.75%)

JNJ

Johnson & Johnson

$136.95

-0.23 (-0.17%)

AMRX

Amneal Pharmaceuticals

$3.24

-0.16 (-4.71%)

ABC

AmerisourceBergen

$90.59

-0.06 (-0.07%)

MCK

McKesson

$150.96

-2.38 (-1.55%)

  • 07

    Dec

  • 22

    Jan

TEVA Teva
$10.57

-0.145 (-1.35%)

11/12/19
JPMS
11/12/19
UPGRADE
Target $8
JPMS
Neutral
JPMorgan upgrades Teva to Neutral on stabilizing fundamentals
JPMorgan analyst Christopher Schott upgraded Teva Pharmaceuticals to Neutral from Underweight with an unchanged price target of $8. The analyst, who remains "fairly bearish" on the company's longer term setup, cites valuation for the upgrade with the stock down 55% year-to-date. Further, Teva's near-to-mid-term fundamentals are stabilizing, unlike some of its peers, Schott tells investors in a research note. As such, the analyst sees a "decidedly less-negative" setup today than several months ago.
11/12/19
11/12/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Argo Group (ARGO) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Christopher Campbell saying he believes the company's "sizable" Q4 International reserve charge will restore balance sheet confidence and that new CEO Kevin Rehnberg's U.S. Operations outperformance can be replicated in its International segment. 2. Live Nation (LYV) upgraded to Outperform from In Line at Evercore ISI with analyst David Joyce saying he believes Live Nation shares have "pulled back needlessly" following its Q3 earnings results, and recommended taking advantage of the pullback. 3. Rent-A-Center (RCII) upgraded to Buy from Hold at Stifel with analyst John Baugh saying the recent pullback in the shares creates an attractive entry point. 4. Crowdstrike (CRWD) upgraded to Neutral from Sell at Goldman Sachs with analyst Heather Bellini she sees a more balanced risk/reward with the stock down 23% since her October 11 downgrade to Sell. 5. Teva (TEVA) upgraded to Neutral from Underweight at JPMorgan with analyst Christopher Schott citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/19
OPCO
11/18/19
NO CHANGE
Target $12
OPCO
Outperform
Teva may be positioned to sustain U.S. generic revenue base, says Oppenheimer
Oppenheimer analyst Esther Rajavelu reviewed Teva's U.S. generic trends, saying that based on her firm's analysis, compared to 2017, GtN discounts may have narrowed during 2019, a higher proportion of Teva's current portfolio competes with fewer manufacturers, and more 2019 launches are in markets with less than or equal to 2 competitors. Based on these metrics, Rajavelu says Teva may be better positioned to sustain its U.S. generic revenue base. She keeps an Outperform rating and $12 price target on the shares.
11/20/19
JEFF
11/20/19
NO CHANGE
Target $9
JEFF
Hold
Teva 'offered little' on progress toward opioids settlement, says Jefferies
Jefferies analyst David Steinberg said Teva CEO Kare Schultz has "largely delivered" on stabilizing Teva's financials over the past two years on the job, but opioid litigation has overwhelmed the fundamentals lately. After hosting investor meetings at the company's headquarters in Israel, Steinberg said Teva "offered little in the way of tangible progress" toward getting its proposed opioid settlement approved by all the relevant parties. Steinberg, who notes that there are still 46 state attorneys general that need to opt in, said he believes that "seems uncertain" to happen. Given the opioid litigation is "clouding an already uncertain future," Steinberg keeps a Hold rating and $9 price target on Teva shares, though he added that management believes that the market is just about at the price stabilization phase of the generic drug pricing cycle.
MNK Mallinckrodt
$3.74

0.135 (3.75%)

09/05/19
09/05/19
DOWNGRADE
Target $3

Market Perform
Mallinckrodt cut to Market Perform at BMO Capital on opioid restructuring report
As previously reported, BMO Capital analyst Gary Nachman downgraded Mallinckrodt to Market Perform and slashed his price target to $3 from $19 after yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. The analyst contends that an already challenging situation has "taken a turn for the worse", stating that he previously believed that the company would be able to navigate through these issues. Nachman adds that with the mounting pressures related to the litigation, the possibility of bankruptcy for Mallinckrodt can no longer be ruled out.
09/10/19
STFL
09/10/19
NO CHANGE
STFL
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
Stifel analyst Annabel Samimy maintained a Hold rating and $8 price target on Mallinckrodt, but noted that Mallinckrodt announced the sale of its CDMO organization, BioVectra, to HIG Capital for a potential $250M, which the analyst believes is "a positive step to manage and bolster cash and maintain capital allocation priorities." Samimy added that, with the departure of Specialty Generics President Matthew Harbaugh, the company's suspension of the spin-off appears indefinite.
09/09/19
STFL
09/09/19
NO CHANGE
Target $8
STFL
Hold
Mallinckrodt price target lowered to $8 from $20 at Stifel
Stifel analyst Annabel Samimy lowered her price target for Mallinckrodt shares to $8 from $20 after she reduced her expected growth of Acthar for 2019 and beyond and factored in more concrete potential litigation cash-calls. She models a $300M potential settlement with CMS related to the Acthar AMP-pricing reversion and has included a $900M potential liability for opioid-litigation payments, calling those her "best, reasonable estimates at this point" but acknowledging there still remains considerable uncertainty around both issues. Mallinckrodt's settlement of Track 1 of the Ohio multi-district litigations is "only a small step in the sprawling opioid litigation," but the settlement buys the company much-needed time to address New York state litigation or a global settlement, said Samimy, who keeps a Hold rating on Mallinckrodt shares.
09/05/19
09/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BHP Group (BHP) downgraded to Underperform from Neutral at Exane BNP Paribas. 2. Mallinckrodt (MNK) downgraded to Market Perform from Outperform at BMO Capital analyst Gary Nachman citing yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. 3. Yirendai (YRD) downgraded to Underperform from Neutral at Macquarie with analyst Dexter Hsu saying the company not only reported "disappointing" Q2 results, but also closed the merger with CreditEase on unfavorable terms. 4. Green Dot (GDOT) downgraded to Hold from Buy at Jefferies with analyst John Hecht saying the company's organic revenue growth has been slowing and it is trying to establish share in a new customer target market with well-resourced competitors. 5. Royal Dutch Shell (RDS.A, RDS.B) downgraded to Market Perform from Outperform at Cowen with analyst Jason Gabelman saying the downgrade reflects its peer leading exposure to international gas prices which are forecasted lower through 2020 and as a result could limit its free cash flow growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JNJ Johnson & Johnson
$136.95

-0.23 (-0.17%)

11/19/19
CANT
11/19/19
INITIATION
Target $160
CANT
Overweight
Johnson & Johnson initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen initiated coverage of Johnson & Johnson with an Overweight rating and $160 price target.
11/20/19
CANT
11/20/19
INITIATION
Target $160
CANT
Overweight
Cantor Fitzgerald starts Johnson & Johnson with Overweight, $160 price target
Cantor Fitzgerald analyst Louise Chen last night initiated coverage of Johnson & Johnson with an Overweight rating and $160 price target. Upwards earnings revisions to J&J's Pharma business and multiple expansion, driven by diminishing headlines risks from talc and opioids, should move the shares higher, Chen tells investors in a research note. She points out that Johnson & Johnson has reported eight consecutive years of pharma operational sales growth of 8.9% annually, about twice as fast as the global market. The analyst also thinks the company's liabilities from talc and opioids are manageable with its cash balance, as well as its cash flow from operations.
11/20/19
11/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) initiated with an Overweight at Cantor Fitzgerald. 2. Brink's (BCO) initiated with a Buy at Goldman Sachs. 3. KLA-Tencor (KLAC) initiated with a Buy at Nomura Instinet. 4. NexTier Oilfield (NEX) initiated with a Buy at Citi. 5. Carrols Restaurant (TAST) initiated with a Buy at Craig-Hallum. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/30/19
MSCO
10/30/19
NO CHANGE
MSCO
Morgan Stanley says J&J talc test 'not an all clear,' but incremental positive
Morgan Stanley analyst David Lewis noted that Johnson & Johnson announced that its independent testing concluded no presence of asbestos in the company's previously recalled baby powder, though the FDA subsequently stated, "They would say the product is free of asbestos based on their testing, and we would say the opposite for that sample." Though the FDA is standing behind its test, Lewis doesn't think this suggests a contentious disagreement, but rather a statement of fact for respective testing. The analyst, who said that he has more work to do to understand the results and protocols, said this news is "not an all clear," but it is an incremental positive.
AMRX Amneal Pharmaceuticals
$3.24

-0.16 (-4.71%)

11/12/19
JPMS
11/12/19
DOWNGRADE
JPMS
Underweight
Amneal Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Christopher Schott downgraded Amneal Pharmaceuticals to Underweight from Neutral.
11/07/19
LEER
11/07/19
DOWNGRADE
Target $3
LEER
Market Perform
Amneal Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
SVB Leerink analyst Ami Fadia downgraded Amneal Pharmaceuticals to Market Perform from Outperform with a price target of $3, down from $4.
11/12/19
11/12/19
INITIATION

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CSX (CSX) downgraded to Hold from Buy at Deutsche Bank. 2. Eaton (ETN) downgraded to Hold from Buy at HSBC. 3. Amneal Pharmaceuticals (AMRX) downgraded to Underweight from Neutral at JPMorgan with analyst Christopher Schott saying while some of the challenges facing the company appear fixable, like supply penalties and plant utilization, many appear fundamental, a function of the evolving dynamics in the U.S. generics market. 4. Albemarle (ALB) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan saying with lithium prices falling below historical levels, global lithium suppliers may have to reduce output and wait for demand to catch up. 5. Box (BOX) downgraded to Market Perform from Outperform at JMP Securities with analyst Erik Suppiger citing concerns that after the challenging October quarter, the pipeline of the company's business has slowed. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/19
JPMS
11/12/19
DOWNGRADE
JPMS
Underweight
Amneal Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Christopher Schott downgraded Amneal Pharmaceuticals to Underweight from Neutral without a price target. While some of the challenges facing the company appear fixable, like supply penalties and plant utilization, many appear fundamental, a function of the evolving dynamics in the U.S. generics market, Schott tells investors in a research note. He believes fixing these will likely take time and resources. At this point, major pipeline successes would be needed to turn Amneal's story around, which appear increasingly unlikely in the near-term, contends the analyst.
ABC AmerisourceBergen
$90.59

-0.06 (-0.07%)

10/16/19
JEFF
10/16/19
NO CHANGE
JEFF
Drug distributor settlement would make stocks 'ownable again,' says Jefferies
Reports that the drug distributors, AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK) have proposed an $18B settlement payable over 18 years to broadly settle outstanding lawsuits resulting from the companies' distribution of opioids should eliminate a longstanding overhang on the group, if finalized, Jefferies analyst Brian Tanquilut tells investors in a research note. With investors generally expecting a settlement of $15B-$25B, payable over a five-to-ten year time frame, the reported settlement proposal should be viewed as a positive, says the analyst. Tanquilut says the $18B payable over 18 years would be better than investors' current expectations. As sector fundamentals are improving, "elimination of long-standing overhang should make the group ownable again," he contends. The analyst prefers Buy-rated McKesson over Hold-rated AmerisourceBergen and Cardinal Health.
10/16/19
LEHM
10/16/19
NO CHANGE
Target $156
LEHM
Equal Weight
Barclays ups McKesson target on probability of favorable settlement
If the $18B drug distributor opioid settlement, as reported last night by the Wall Street Journal, covers nearly all outstanding cases, and does not include any accelerated upfront payments for the industry, then it would likely be viewed net positive by investors and could lead to multiple expansion from current share levels, Barclays analyst Steve Valiquette tells investors in a research note. The analyst believes the possibility of a settlement is greater over the next week ahead of the start of the Ohio multi-district litigation. To reflect a higher probability of a favorable settlement, Valiquette raised his price target for McKesson (MCK) to $156 from $144 while keeping an Equal Weight rating on the shares.
09/11/19
DBAB
09/11/19
INITIATION
Target $91
DBAB
Hold
AmerisourceBergen initiated with a Hold at Deutsche Bank
Deutsche Bank analyst George Hill initiated AmerisourceBergen with a Hold rating and a price target of $91 as part of a broader research note on Healthcare Technology & Services. The analyst is positive on the "structural position" of the wholesalers in the drug supply chain, but warns that the company is faced with issues related to brand drug pricing, generic drug pricing, volumes shifting towards lower-margin customers and opioid litigation.
10/16/19
JEFF
10/16/19
NO CHANGE
JEFF
Drug distributor settlement would make stocks 'ownable again,' says Jefferies
Reports that the drug distributors, AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK) have proposed an $18B settlement payable over 18 years to broadly settle outstanding lawsuits resulting from the companies' distribution of opioids should eliminate a longstanding overhang on the group, if finalized, Jefferies analyst Brian Tanquilut tells investors in a research note. With investors generally expecting a settlement of $15B-$25B, payable over a five-to-ten year time frame, the reported settlement proposal should be viewed as a positive, says the analyst. Tanquilut says the $18B payable over 18 years would be better than investors' current expectations. As sector fundamentals are improving, "elimination of long-standing overhang should make the group ownable again," he contends. The analyst prefers Buy-rated McKesson over Hold-rated AmerisourceBergen and Cardinal Health.
MCK McKesson
$150.96

-2.38 (-1.55%)

10/31/19
JPMS
10/31/19
NO CHANGE
Target $169
JPMS
Overweight
McKesson selloff yesterday a buying opportunity, says JPMorgan
JPMorgan analyst Lisa Gill views the selloff yesterday in shares of McKesson as a buying opportunity. The stock traded down 8% yesterday despite a slight fiscal Q4 adjusted earnings beat and reaffirmed fiscal 2020 adjusted operating profit and adjusted earnings guidance, Gill tells investors in a research note. The analyst does not believe there has been a meaningful deterioration in McKesson's underlying fundamentals. She keeps an Overweight rating on the shares with a $169 price target.

TODAY'S FREE FLY STORIES

WFT

Weatherford

$0.00

(0.00%)

18:49
12/13/19
12/13
18:49
12/13/19
18:49
Hot Stocks
Weatherford completes financial restructuring, emerges from Chapter 11 »

Weatherford announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$57.71

-0.81 (-1.38%)

18:40
12/13/19
12/13
18:40
12/13/19
18:40
Hot Stocks
Centene CEO: Our big markets are growing, we're gaining share »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

LYV

Live Nation

$64.24

-5.205 (-7.50%)

, ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

18:29
12/13/19
12/13
18:29
12/13/19
18:29
Hot Stocks
S&P announces changes to S&P 400, 500, 600 indices »

S&P Dow Jones Indices…

LYV

Live Nation

$64.24

-5.205 (-7.50%)

ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

STE

Steris

$151.93

-1.745 (-1.14%)

AMG

Affiliated Managers

$85.18

-1.77 (-2.04%)

TRIP

TripAdvisor

$29.24

-0.2 (-0.68%)

MAC

Macerich

$26.04

-0.46 (-1.74%)

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

LEA

Lear

$129.43

-0.84 (-0.64%)

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 23

    Mar

PLAN

Anaplan

$51.80

1.44 (2.86%)

18:23
12/13/19
12/13
18:23
12/13/19
18:23
Hot Stocks
Anaplan CEO: Digitization has really started to accelerate »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPX

WPX Energy

$10.92

-0.24 (-2.15%)

18:08
12/13/19
12/13
18:08
12/13/19
18:08
Periodicals
WPX Energy in talks to acquire Felix Energy assets for $2.5B, Bloomberg says »

WPX Energy is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

HLIT

Harmonic

$7.94

-0.25 (-3.05%)

17:47
12/13/19
12/13
17:47
12/13/19
17:47
Hot Stocks
Harmonic CFO sells 28K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$32.84

(0.00%)

17:36
12/13/19
12/13
17:36
12/13/19
17:36
Hot Stocks
Breaking Hot Stocks news story on Horizon Pharma »

Horizon Pharma up 9.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 08

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:33
12/13/19
12/13
17:33
12/13/19
17:33
Hot Stocks
Breaking Hot Stocks news story on Amarin »

Amarin rises 1.4% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

THMO

ThermoGenesis

$2.88

(0.00%)

17:31
12/13/19
12/13
17:31
12/13/19
17:31
Syndicate
Breaking Syndicate news story on ThermoGenesis »

ThermoGenesis files $30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

17:30
12/13/19
12/13
17:30
12/13/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Amarin 

Amarin trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

QTNT

Quotient

$8.60

-0.165 (-1.88%)

17:28
12/13/19
12/13
17:28
12/13/19
17:28
Syndicate
Breaking Syndicate news story on Quotient »

Quotient files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

, GVA

Granite Construction

$26.21

-1.335 (-4.85%)

17:27
12/13/19
12/13
17:27
12/13/19
17:27
Hot Stocks
Breaking Hot Stocks news story on Arrowhead, Granite Construction »

Arrowhead to replace…

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

, SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

17:25
12/13/19
12/13
17:25
12/13/19
17:25
Hot Stocks
Oasis, Southwestern to replace Unit Corp., Frontier in S&P 600 at open on 12/23 »

Oasis Petroleum (OAS) and…

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:24
12/13/19
12/13
17:24
12/13/19
17:24
Hot Stocks
Amarin raises guidance after FDA approves Vascepa »

Amarin (AMRN) shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

, LEA

Lear

$129.43

-0.84 (-0.64%)

17:22
12/13/19
12/13
17:22
12/13/19
17:22
Hot Stocks
Grand Canyon, Lear to replace Oasis, Southwestern in S&P 400 at open on 12/23 »

Grand Canyon Education…

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

LEA

Lear

$129.43

-0.84 (-0.64%)

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

RTN

Raytheon

$217.31

-0.93 (-0.43%)

17:20
12/13/19
12/13
17:20
12/13/19
17:20
Hot Stocks
Raytheon awarded $123.53M Navy contract modification »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYV

Live Nation

$64.24

-5.205 (-7.50%)

, ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

17:19
12/13/19
12/13
17:19
12/13/19
17:19
Hot Stocks
Live Nation, Zebra Technologies, Steris to move to S&P 500 at open on 12/23 »

Live Nation (LYV), Zebra…

LYV

Live Nation

$64.24

-5.205 (-7.50%)

ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

STE

Steris

$151.93

-1.745 (-1.14%)

AMG

Affiliated Managers

$85.18

-1.77 (-2.04%)

TRIP

TripAdvisor

$29.24

-0.2 (-0.68%)

MAC

Macerich

$26.04

-0.46 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

BAESY

BAE Systems

$0.00

(0.00%)

17:15
12/13/19
12/13
17:15
12/13/19
17:15
Hot Stocks
BAE Systems awarded $249.15M Army contract modification »

BAE Systems was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WST

West Pharmaceutical

$146.32

-0.14 (-0.10%)

17:02
12/13/19
12/13
17:02
12/13/19
17:02
Hot Stocks
West Pharmaceutical announces 848K share repurchase authorization »

On December 10, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

17:02
12/13/19
12/13
17:02
12/13/19
17:02
Earnings
Amarin sees FY20 revenue $650M-$700M, consensus $654.55M »

With respect to 2020,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

IBIO

iBio

$0.22

-0.0179 (-7.43%)

17:01
12/13/19
12/13
17:01
12/13/19
17:01
Hot Stocks
iBio receives NYSE noncompliance notice »

iBio, Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLT

Applied Therapeutics

$21.23

0.29 (1.38%)

16:59
12/13/19
12/13
16:59
12/13/19
16:59
Syndicate
Breaking Syndicate news story on Applied Therapeutics »

Applied Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:59
12/13/19
12/13
16:59
12/13/19
16:59
Earnings
Amarin raises FY19 revenue view to $410M-$425M from $380M-$420M 

FY19 consensus $410.25M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

BIO

Bio-Rad

$354.69

-8.005 (-2.21%)

16:56
12/13/19
12/13
16:56
12/13/19
16:56
Hot Stocks
Bio-Rad progressing from ransomware attack recovery detected on Dec 5th »

Bio-Rad Laboratories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:50
12/13/19
12/13
16:50
12/13/19
16:50
Hot Stocks
Amarin confirms FDA approval of Vascepa »

Amarin announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.